Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicainoprol SCHEMBL11282827 | 0.92 | HSD17B10 (0.44) | HSD17B10POLBADRB2ADRB1ADRB3 | |
| SCHEMBL11271377 | 0.89 | POLB (0.47) | HSD17B10POLBADRB2ADRB1ADRB3 | |
| SCHEMBL10652857 | 0.86 | POLB (0.51) | HSD17B10POLBNR2E1ALDH1A1LMNA | |
| Oxalic Acid SCHEMBL10574298 | 0.84 | POLB (0.49) | HSD17B10POLBALDH1A1LMNASMN1; SMN2 | |
| Oxalic Acid SCHEMBL10569361 | 0.83 | POLB (0.48) | HSD17B10POLBCYP1A2CYP2D6NR2E1 | |
| Oxalic Acid SCHEMBL10569733 | 0.83 | POLB (0.48) | HSD17B10POLBCYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL11149363 | 0.82 | ADRB2 (0.56) | HSD17B10POLBADRB2ADRB1ADRB3 | |
| SCHEMBL11271380 | 0.79 | POLB (0.52) | HSD17B10POLBALDH1A1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10572689 | 0.79 | POLB (0.55) | HSD17B10POLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10570434 | 0.78 | POLB (0.50) | HSD17B10POLBCYP1A2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021116487-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF NIEMANN-PICK C DISEASE | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-06-17 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4335123-A | HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1982-06-15 | — | — | US | claimed |
| EP-0025864-A1 | Tetrahydroquinoline derivatives, processes for their production, their use and pharmaceutical preparations containing them | CASSELLA Aktiengesellschaft (DE) | 1981-04-01 | — | — | EP | claimed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-4845099-A | ANTIARRHYTHMIA AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| EP-0025864-B1 | TETRAHYDROQUINOLINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, THEIR USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CASSELLA Aktiengesellschaft (DE) | 1983-05-18 | — | — | EP | disclosed |
| US-4335123-A | HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1982-06-15 | — | — | US | disclosed |
| EP-0025864-A1 | Tetrahydroquinoline derivatives, processes for their production, their use and pharmaceutical preparations containing them | CASSELLA Aktiengesellschaft (DE) | 1981-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | HSD17B10 4639/4885POLB 4448/4885ADRB2 1548/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | HSD17B10 3866/4885POLB 3254/4885ADRB2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.